SCHEMBL29327889

SCHEMBL29327889

CCc1ccc(-c2nc3ccc(NC(=O)c4cc(C#N)ccc4S(C)(=O)=O)cc3s2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 7/20 0.56
▸ TP53 P04637 4/20 0.56
▸ APP P05067 3/20 0.51
▸ PPARG P37231 1/20 0.50
▸ THRB P10828 1/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ RORC P51449 3/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ LMNA P02545 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ GAA P10253 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ SULT1A1 P50225 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ PKM P14618 1/20 0.41
▸ KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29327883 0.93 PPARG (0.52) MAPTTP53APPPPARGTHRB
SCHEMBL29327928 0.92 APP (0.48) MAPTTP53APPPPARGTHRB
SCHEMBL29327980 0.86 MAPT (0.53) MAPTTP53APPPPARGSMN1; SMN2
SCHEMBL29328000 0.86 MAPT (0.49) MAPTTP53APPPPARGTHRB
SCHEMBL29327924 0.85 PPARG (0.49) MAPTTP53APPPPARGTHRB
SCHEMBL29327950 0.84 MAPT (0.50) MAPTTP53APPSMN1; SMN2RORC
SCHEMBL29327605 0.82 PPARG (0.67) MAPTTP53PPARGTHRBSMN1; SMN2
SCHEMBL29327607 0.81 PPARG (0.55) MAPTTP53PPARGTHRBRORC
SCHEMBL29327587 0.80 PPARG (0.77) MAPTTP53PPARGSMN1; SMN2NPC1
SCHEMBL29327871 0.79 PPARG (0.48) TP53PPARGTHRBNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF FLARE THERAPEUTICS INC. 2024-07-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240239760-A1 PPARG INVERSE AGONISTS AND USES THEREOF PPARG, PPARA, PPARD MAPT 4591/4885TP53 1398/4885APP 3242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback